Quick Order Cart

Cat. No. ARG44092

RNF213 Knockout HEK293T Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Kidney

The RNF213 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited knockout cell line lacking the E3 ubiquitin ligase RNF213, a key regulator of NF-??B signaling that mediates I??B?? degradation and VEGF expression. This model is relevant for Moyamoya disease research, ubiquitination pathway analysis, and angiogenesis studies. Based on the highly transfectable HEK293T epithelial host, the line is ideal for NF-??B reporter assays, VEGF ELISA, tube formation, and wound healing migration assays, supporting comprehensive analysis of RNF213??s role in vascular biology, lipid metabolism, and Moyamoya disease.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HEK293T

    Sex of Donor

    Female

    Age

    Fetus

    Derived From Site

    Fetal kidney

    Gene Name

    RNF213

    Gene Identifier

    NCBI Gene ID 57674

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The RNF213 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited knockout cell line featuring disruption of the human RNF213 gene in the HEK293T epithelial host. This loss-of-function model provides a stable platform for investigating RNF213-dependent mechanisms in cellular signaling, protein ubiquitination, and angiogenesis. The cell line is suitable for a wide range of downstream analyses, including gene rescue and pathway interrogation.

HEK293T is a human embryonic kidney cell line transformed with adenovirus type 5 DNA and expressing SV40 large T antigen, resulting in high transfection efficiency and robust protein production. Its epithelial origin makes it a convenient system for studying cell migration, barrier function, and signaling pathways relevant to disease. The cell line??s ease of manipulation and well-characterized background support reliable and reproducible experiments across diverse research areas.

RNF213 encodes an E3 ubiquitin ligase that activates NF-??B signaling by promoting ubiquitin-dependent degradation of I??B??, thereby liberating NF-??B p65 to drive transcription of downstream targets such as VEGF. Its activity is modulated by upstream stimuli including interferon-gamma, NF-??B, and hypoxia, and it interacts with filamin A and caveolin-1 to influence actin cytoskeleton remodeling. Consequently, loss of RNF213 disrupts NF-??B?Cmediated gene expression and cytoskeletal dynamics, linking it to vascular homeostasis and Moyamoya disease.

In the HEK293T background, this knockout cell line enables precise dissection of RNF213 function without endogenous interference. The high transfectability of the host facilitates complementation studies and reporter assays, allowing rapid assessment of mutant RNF213 variants or small-molecule modulators. Furthermore, the epithelial context supports investigations into RNF213??s roles in cell motility, inflammatory responses, and metabolic regulation.

Key research applications include dissecting Moyamoya disease mechanisms through analysis of NF-??B signaling dysregulation and impaired angiogenesis, studying RNF213-mediated ubiquitination using ubiquitination assays and co-immunoprecipitation of interacting partners such as filamin A and caveolin-1, and exploring lipid droplet biology with lipid droplet staining. The cell line supports functional assessments via NF-??B reporter assays, VEGF ELISA, tube formation, and wound healing migration assays, complemented by western blotting and RT-qPCR for target validation. For additional product details or to initiate a purchase, please reach out to Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)